The company said in a 24-week phase 2a study with 16 patients the drug showed "favorable safety, tolerability, and therapeutic effect."
Hereditary hemochromatosis is a genetic disorder that causes the body to absorb too much iron, Protagonist said.
Price: 37.24, Change: +0.14, Percent Change: +0.38
|Covetrus Says it Gets Proposal From Clayton, Dubilie...|
|--April Unemployment Rate Fell in 13 US States, Payr...|
|Marvell Technology Likely to See Fiscal Q1 Beat, Opp...|
|Research Alert: CFRA Keeps Buy Opinion On Shares Of ...|
|Terreno Realty Acquires Newark Industrial Property f...|